Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × ALK Gene Rearrangement Positive × alectinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 12 Urinary Bladder Neoplasms 1 Neoplasms, Unknown Primary 1 Neoplasms 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Glioblastoma 1 Carcinoma, Hepatocellular 1 Biliary Tract Neoplasms 1 Advanced Unresectable or Metastatic Solid Malignancy 1 Adenocarcinoma of Lung 1 ALK-positive NSCLC 1 ALK+ Advanced NSCLC 1 ALK Gene Rearrangement Positive 1

Interventions

alectinib 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03779191 2023-07-06

Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Instituto Nacional de Cancerologia de Mexico

Phase 2 Completed

ALK Gene Rearrangement Positive

Data powered by HemOnc (CC BY 4.0) Colophon ⚡